HLA-restricted presentation of WT1 tumor antigen in B-lymphoblastoid cell lines established using a maxi-EBV system

Kanda, Teru; Ochi, Toshiki; Fujiwara, Hiroshi; Yasukawa, Masaki; Okamoto, Sachiko; Mineno, Junichi; Kuzushima, Kiyotaka; Tsurumi, Tatsuya

doi:10.1038/cgt.2012.34

Cited by 2 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Constant research have been conducted into various DC alternatives that could be essential in inducing favorable immune response. Lymphoblastoid cell lines (LCLs) have been investigated as promising alternative APCs for eliciting cytotoxic T cell responses against viruses and cancers [ 37 – 39 ]. Most importantly, LCLs can be easily obtained from Epstein-Barr virus (EBV)-positive humans [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Human γδ T cells induce CD8+ T cell antitumor responses via antigen-presenting effect through HSP90-MyD88-mediated activation of JNK

Wang

Chen

et al. 2023

Cancer Immunol Immunother

View full text Add to dashboard Cite

Human Vγ9Vδ2 T cells have attracted considerable attention as novel alternative antigen-presenting cells (APCs) with the potential to replace dendritic cells in antitumor immunotherapy owing to their high proliferative capacity and low cost. However, the utility of γδ T cells as APCs to induce CD8+ T cell-mediated antitumor immune response, as well as the mechanism by which they perform APC functions, remains unexplored. In this study, we found that activated Vγ9Vδ2 T cells were capable of inducing robust CD8+ T cell responses in osteosarcoma cells. Activated γδ T cells also effectively suppressed osteosarcoma growth by priming CD8+ T cells in xenograft animal models. Mechanistically, we further revealed that activated γδ T cells exhibited increased HSP90 production, which fed back to upregulate MyD88, followed by JNK activation and a subsequent improvement in CCL5 secretion, leading to enhanced CD8+ T cell cross-priming. Thus, our study suggests that Vγ9Vδ2 T cells represent a promising alternative APC for the development of γδ T cell-based tumor immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%